Vivesto AB
The answer first
Does Vivesto beat the market?
No, Vivesto has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 32% of Nordic stocks
- Quality61
- Value58
- Trend7
No. 98 of 195 in healthcare
Max for seven days
Follow Vivesto with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Vivesto
Your first answer is free, no account needed.
Do you own Vivesto, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Vivesto and a few more. Free, no card.
Super Stock+44.6%In short
- Vivesto has fallen 64.8% over the past year, including dividends.
- Overall, Vivesto ranks better than 32% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.2%. The price is 99.6% below its peak now.
What do analysts think of Vivesto?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 32% of Nordic stocks.
No. 98 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 105 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.13
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−20.1%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 33 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.5
- P/SPrice divided by salesnegative earnings
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 164 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−19.0%
- 6 months−50.4%
- 9 months−14.3%
- 12 months−64.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Vivesto
Vivesto AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
Vivesto AB (publ) develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB (publ) in March 2022.


See the full analysis of Vivesto.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card